3131-64-4

Upstream product

• 533-58-4 2-Iodophenol 
• 99845-86-0 1-phenylpenta-2,3-dien-1-one 
• 20913-05-7 (Benzoylmethylene)triphenylphosphorane 
• 100-52-7 benzaldehyde 
• 90-02-8 salicylaldehyde 
• 1646-26-0 1-(benzo[b]furan-2-yl)ethanone 
• 3131-63-3 2-ethylbenzofuran 
• 98-88-4 benzoyl chloride 

Downstream Products

• 93315-86-7 (2-ethyl-benzofuran-3-yl)-phenyl ketone oxime 
• 1031-80-7 2-(3-ethyl-5-phenyl-isoxazol-4-yl)-phenol 
• 29936-03-6 N-[4-ethyl-5-(2-hydroxy-phenyl)-6-phenyl-pyrimidin-2-yl]-morpholine-4-carboximidic acid amide 
• 27356-33-8 2-(2-methoxyphenyl)-1-phenylethan-1-one 
• 27432-39-9 1-(2-methoxyphenyl)butan-2-one 
• 101596-60-5 (2-ethyl-benzofuran-3-yl)-phenyl-methanol 

Relevant academic research and scientific papers

Synthesis of 2-vinylbenzofurans via the copper-catalyzed multicomponent reactions involving an oxa-michael/arylation/vinylation cascade

2-Vinylbenzofurans have been synthesized via the copper-catalyzed one-pot, three-component reactions of o-iodophenols, in situ generated allenes, and dichloromethane. Cascade transformation of oxa-Michael addition, C-arylation, and sp3C-H/spsu

Copper-catalyzed, C-C coupling-based one-pot tandem reactions for the synthesis of benzofurans using o-iodophenols, acyl chlorides, and phosphorus ylides

One-pot reactions involving acyl chlorides, phosphorus ylides, and o-iodophenols with copper catalysis have been established for the rapid synthesis of functionalized benzofurans. With all of these easily available and stable reactants, the construction o

DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION

A compound represented by the general Formula (I): a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a pro-drug thereof, a deuterated radio-labeled analog thereof, and mixtures of any of the foregoing, wherein: A - K are individually selected from carbon or nitrogen; X = -O, -NR1,or -S; R1-11 are individually selected from the group consisting of-H, C1-C6 alkyl, C6-C aryl, substituted C6-C14 aryl, C1-C14-alkoxy, halogen, hydroxyl, carboxy, cyano, C1-C6-alkanoyloxy, C1-C6-alkylthio, C1-C6-alkylsulfonyl, trifluoromethyl, hydroxy, C2-C6-alkoxycarbonyl, C2-C6-alkanoylamino, -O-R12, S-R12,-SO2-Ri2, -NHSO2R12 and -NHCO2R12, wherein R12 is phenyl, naphthyl, or phenyl or naphthly substituted with one to three groups selected from C1-C6-alkyl, C6-C10 aryl,C1-C6-alkoxy and halogen, and C4-C20 hydroxyheteroaryl wherein the heteroatoms are selected from the group consisting of sulfur, nitrogen, and oxygen.

Human uric acid transporter 1 (hURAT1): An inhibitor structure-activity relationship (SAR) study

The current study describes the chemical synthesis of a series of (2-ethylbenzofuran-3-yl)(substituted-phenyl)methanone compounds and their subsequent in vitro testing via oocytes expressing hURAT1. The experimental data support the notion that a potent hURAT1 inhibitor requires an anion (i.e., a formal negative charge) to interact with the positively charged hURAT1 binding pocket. An anion appears to be a primary requirement in order to be a hURAT1 substrate (i.e., urate) or inhibitor. We discuss the inhibitor structure-activity relationship and how electronically donating or withdrawing groups attached to the B-ring can decrease or increase inhibitory potency, respectively. Copyright Taylor and Francis Group, LLC.

Substituted oxadiazolidinediones

The present invention relates generally to substituted oxadiazolidinediones and methods of using them.